? Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally ? ? Following ...
Q. I don’t trust my child’s father. He says one thing and does another—all the time. I get to the point where I think maybe, just maybe, I can trust ...
After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...